Prodrome Sciences Inc. is pleased to announce a distribution agreement with Neo Sanguis Srl for the sale of Prodrome Sciences’ multi-analyte risk assessment tests in Romania. Prodrome-CRC, a blood test to determine colorectal cancer risk, is the first product to launch in the region. Neo Sanguis Srl is based in Romania and offers specialty diagnostics products.
Prodrome Sciences has developed improved blood testing technology to identify persons with a high risk of colorectal cancer. The new test, Prodrome-CRC, uses Prodrome Sciences’ patented high-resolution/accurate-mass technology to simultaneously measure multiple biomarkers associated with an increased risk of colorectal cancer.
Prodrome Sciences is an integrated molecular diagnostics and therapeutics company focused on the early detection and prevention of disease. The Company uses its patented comprehensive metabolomics technology to discover prodromes of diseases; prodromes are states of biochemical imbalance that occur before disease symptoms appear. Prodrome Sciences develops blood tests to detect prodromes of diseases and therapeutics to restore unhealthy biochemical imbalances to a healthy state. The goal is to reduce the number of people that develop and die from disease and to promote optimal health and longevity.
Please contact us for more information.